Regeneron Pharmaceuticals Inc (MIL:1REGN)
€ 757 -25.2 (-3.22%) Market Cap: 83.82 Bil Enterprise Value: 77.30 Bil PE Ratio: 20.53 PB Ratio: 3.11 GF Score: 79/100

Regeneron Pharmaceuticals Inc at RBC Capital Markets Global Healthcare Conference (Virtual) Transcript

May 18, 2021 / 12:00PM GMT
Kennen B. MacKay
RBC Capital Markets, Research Division - MD & Co-Head of US Biotechnology Research

Hi. My name is Kennen MacKay. I'm one of the biotech analysts here at here at RBC, and it's my great pleasure to be kicking off our 2021 Virtual Healthcare Conference with Regeneron Pharmaceuticals. From Regeneron, we have Dr. Neil Stahl, the Executive Vice President of R&D; Jamie Orengo, the Vice President of Research, Allergy and Immunity; and Justin Holko, who heads up Communications and IR.

And Justin, I'll pass it to you, before jumping in, to give some of your prepared statements. Go ahead.

Justin Holko
Regeneron Pharmaceuticals, Inc. - VP of IR

Great. Thank you, Kennen. Before we begin, I'd just like to remind everybody that remarks made on today's webcast will include forward-looking statements about Regeneron, including those related to R&D, in particular. Each forward-looking statement is subject to risks and uncertainties that could cause actual results and events to differ materially from those projected in that statement. More

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot